Thermo Fisher has priced an offering of $2.2bn senior notes to pay for its planned acquisition of Qiagen. The news comes the same week, Qiagen confirmed Thierry Bernard as permanent CEO following the departure of former leader Peer Schatz.
Thierry Bernard has been confirmed as the permanent CEO of Qiagen NV, the Netherlands-based diagnostics company announced on 24 March.
Bernard has held the role on an interim basis since October 2019 and has been overseeing Qiagen’s deal to be acquired by Thermo Fisher Scientific, announced earlier this month....
Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.
Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.
During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.
Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
